NCT05940844 2025-04-09
Study of OB-002 in Patients With Refractory Metastatic Cancer
Orion Biotechnology Polska Sp. z o.o.
Phase 1 Withdrawn
Orion Biotechnology Polska Sp. z o.o.
ImmunityBio, Inc.
EMD Serono
Sumitomo Pharma America, Inc.
4D pharma plc
Silverback Therapeutics
UroGen Pharma Ltd.
Eli Lilly and Company